%PDF-1.5
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
uuid:df4c6146-4a47-4604-b5c0-1e9e858f7c2a
adobe:docid:indd:9989c782-f85b-11dd-9209-f11a4b83bb63
xmp.id:485adf4b-63b2-424a-916f-ce135a65b8d0
proof:pdf
xmp.iid:2888e210-ec93-8b41-9d85-642fbdb74129
xmp.did:1F4E2A71EA8AE1118807BF45EE36532B
adobe:docid:indd:9989c782-f85b-11dd-9209-f11a4b83bb63
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2019-04-08T14:19:38-05:00
2019-04-08T14:19:38-05:00
2019-04-08T14:19:38-05:00
2019-04-08T14:19:38-05:00
Adobe InDesign CC 2017 (Windows)
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
50 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
8 0 0 8 55.2728 45.7366 Tm
(8)Tj
ET
q
0 g
/GS0 gs
0 TL/Fm1 Do
Q
0 0 0 1 K
0.25 w 4 M
q 1 0 0 1 297 405 cm
0 0 m
0 -333 l
S
Q
BT
/T1_0 1 Tf
0.275 Tw 10 0 0 10 54 396.4901 Tm
[(focuses on the fundamentals of acute and chr)6.1 (onic pain )]TJ
0 Tw 0 -1.3 TD
[(management and the safe pr)10.1 (escribing of opioids.)]TJ
0.065 Tw 0 -2.02 TD
[(O)6 (n A)17.9 (ugust 2, 2017, the U.S. A)6.1 (ttorney G)6 (eneral announced )]TJ
0.18 Tw 0 -1.3 TD
[(the formation of the O)6 (pioid F)36 (raud and A)12 (buse D)6 (etection )]TJ
0.04 Tw T*
[(U)36 (nit, )0.5 (a )0.6 (U.S. )0.5 (D)6 (epar)-8 (tment )0.6 (of )0.5 (J)36 (ustice )0.5 (pilot )0.6 (pr)6 (ogram. )0.6 (\037e )0.5 (unit )]TJ
0.503 Tw T*
[(will focus speci\036cally on identifying and pr)6 (osecuting )]TJ
0.32 Tw T*
[(physicians and pharmacies that ar)10 (e contributing to the )]TJ
0.367 Tw T*
[(opioid crisis thr)6.1 (ough illegal pr)10.1 (escribing and dispensing )]TJ
0 Tw T*
(practices.)Tj
0.02 Tw 0 -2.02 TD
[(\037e federal go)16 (v)6 (ernment also has mo)16 (v)6 (ed to incr)10 (ease access to )]TJ
0.028 Tw 0 -1.3 TD
[(tr)10 (eatment for individuals with OUD. F)36 (or example, e\034ectiv)6 (e )]TJ
0.145 Tw T*
[(A)18 (ugust 8, 2016, U.S. D)5.9 (epar)-7.9 (tment of H)18 (ealth and H)30 (uman )]TJ
0.178 Tw T*
[(S)12 (er)-18 (vices )0.6 (r)-8 (ules )0.5 (authoriz)6.1 (e )0.5 (incr)10 (eased )0.6 (av)6 (ailability )0.6 (of )0.5 (the )0.5 (MA)70.1 (T )]TJ
0.495 Tw T*
[(dr)-8 (ug bupr)10 (enorphine and combination bupr)10 (enorphine\226)]TJ
0.163 Tw T*
[(nalo)6 (x)6 (one. E)12 (ligible pr)6 (o)16 (viders may tr)10 (eat up to 275 patients )]TJ
-0.011 Tw T*
[(with these medications. P)30 (r)10 (eviously)85 (, pr)6 (o)16 (viders w)6 (er)10 (e limited to )]TJ
0 Tw T*
[(tr)10 (eating 100 patients.)]TJ
0.208 Tw 0 -2.02 TD
[(I)12 (n addition, on F)36 (ebr)-8 (uar)-17.9 (y 15, 2018, SAMHSA published )]TJ
-0.012 Tw 0 -1.3 TD
[(T)130 (r)10 (eatment I)12 (mpr)6 (o)16 (v)6 (ement P)30 (r)6 (otocol \()-11.9 (TIP\) 63, M)24 (edications for )]TJ
0.107 Tw T*
[(O)6 (pioid U)30 (se D)12 (isor)14.1 (der)60 (, which r)10 (evie)-6 (ws the thr)10 (ee MA)70 (T dr)-8 (ugs )]TJ
-0.002 Tw T*
[(appr)6 (o)16 (v)6.1 (ed b)6 (y the FDA to tr)10 (eat OUD. \037e )45.4 (TIP is intended to )]TJ
0.347 Tw T*
[(expand )0.6 (healthcar)10 (e )0.6 (pr)6 (ofessionals)40 (\222 )0.5 (understanding )0.6 (of )0.6 (MA)70 (T )]TJ
-0.071 Tw T*
[(dr)-8 (ugs and e\034ectiv)6.1 (e strategies )0.5 (for suppor)-8 (ting patients )0.5 (r)10 (eceiving )]TJ
-0.12 Tc 0.12 Tw T*
[(M)-120 (A)-50 (T.)]TJ
ET
10 M
/GS2 gs
q 1 0 0 1 54 670.2306 cm
0 0 m
393.84 0 l
S
Q
q 1 0 0 1 447.84 670.2306 cm
0 0 m
92.16 0 l
S
Q
q 1 0 0 1 54 646.111 cm
0 0 m
393.84 0 l
S
Q
q 1 0 0 1 447.84 646.111 cm
0 0 m
92.16 0 l
S
Q
q 1 0 0 1 54 423.4813 cm
0 0 m
393.84 0 l
S
Q
q 1 0 0 1 447.84 423.4813 cm
0 0 m
92.16 0 l
S
Q
BT
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw 9 0 0 9 58.5 696.3306 Tm
(FIGURE 7)Tj
3.92 0 Td
( )Tj
-3.92 -1.2 Td
[(SELECT FEDERAL FUNDING FOR OPIOID CRISIS RECEIVED BY THE ST)71.7 (A)60.1 (TE OF TEXAS)]TJ
0 -1.2 TD
[(FEDERAL FISCAL YEARS 2014 T)11.1 (O 2018)]TJ
8 0 0 8 58.5 650.6111 Tm
[(GRANT PR)40.2 (OGRAM)]TJ
50.374 1.2 Td
(FEDERAL FUNDING )Tj
-1.1 -1.2 Td
(RECEIVED \(IN MILLIONS\))Tj
/TT2 1 Tf
-49.274 -1.853 Td
[(Substance )54.8 (Abuse Prevention and )16.9 (T)37.2 (reatment Block Grant \226 formula funding available to every state for )]TJ
T*
(prevention, treatment, and rehabilitation activities to address alcohol \
and drug abuse)Tj
54.879 1.2 Td
($713.7)Tj
-54.879 -3.053 Td
[(State )18.3 (T)111 (argeted Response to the Opioid Crisis Grants \226 formula funding availa\
ble to every state for )]TJ
T*
(prevention, treatment, and recovery activities for opioid use disorder)Tj
54.879 1.2 Td
($101.0)Tj
-54.879 -3.053 Td
[(Strategic Prevention Framework \226 Partnership for Success, State and )16.6 (T)37.3 (ribal Initiative \226 funding competitively )]TJ
T*
(awarded to states to combat underage drinking and prescription drug misu\
se and abuse among teenagers )Tj
T*
(and young adults through prevention activities)Tj
55.991 2.4 Td
($4.9)Tj
-55.991 -4.253 Td
(Strategic Prevention Framework Rx \226 funding competitively awarded to \
states to combat prescription drug )Tj
T*
(misuse and abuse, primarily through awareness activities)Tj
55.991 1.2 Td
($1.1)Tj
/C2_0 1 Tf
-55.991 -3.053 Td
[<0029004C00550056005700030035004800560053005200510047004800550003>17.5 <0037>37.2 <00550044004C0051004C0051004A000300B100030049005800510047004C0051004A0003004600520050005300480057004C0057004C00590048004F005C00030044005A0044005500470048004700030057005200030056005700440057004800560003005700520003005700550044004C0051000300440051004700030053005500520059004C004700480003005500480056005200580055004600480056000300570052000300BF0055005600570003>]TJ
/TT2 1 Tf
T*
(responders and others regarding carrying and administering opioid overdo\
se reversal drugs)Tj
55.991 1.2 Td
($1.6)Tj
-55.991 -3.053 Td
[(Y)91.8 (outh )17.9 (T)37.3 (reatment \226 Planning and Implementation \226 funding competitively awa\
rded to states to expand and )]TJ
T*
(improve treatment for adolescents with substance use disorder and/or co-\
occurring substance use and )Tj
T*
(mental health disorders)Tj
55.991 2.4 Td
($2.0)Tj
-55.991 -4.253 Td
(Harold Rogers Prescription Drug Monitoring Program: Implementation and E\
nhancement Grants \226 funding )Tj
T*
(competitively awarded to states to plan, implement, or enhance their pre\
scription drug-monitoring programs)Tj
55.991 1.2 Td
($0.5)Tj
/C2_0 1 Tf
7.5 0 0 7.5 58.5 445.9813 Tm
<00310D970D9C0D8D>Tj
/TT2 1 Tf
[(: Not an exhaustive list of federal funding received and expended relate\
d to the opioid crisis. )14 (This list does not include federal funding )]TJ
T*
(received by local communities and community organizations. Some grants a\
re used generally for substance abuse services.)Tj
/C2_0 1 Tf
T*
<00360D970D9D0D9A0D8B0D8D>Tj
/TT2 1 Tf
[(: Substance )55.1 (Abuse and Mental Health Services )53.6 (Administration; U.S. Department of Justice, Bureau of Justice )54.3 (Assistance.)]TJ
/T1_0 1 Tf
0.122 Tw 10 0 0 10 307.8 396.4901 Tm
[(F)34 (inally)85 (, the SUPPOR)45 (T for P)42 (atients and Communities A)12 (ct )]TJ
0.24 Tw 0 -1.3 TD
[(incr)10 (eases access to SUD tr)10.1 (eatment for Childr)10 (en)70 (\222)80 (s H)18 (ealth )]TJ
-0.031 Tw T*
[(I)12 (nsurance P)30 (r)6 (ogram \(CHIP\), M)24 (edicaid, and M)24 (edicar)10 (e clients. )]TJ
0.042 Tw T*
[(\037e legislation mandates state co)16.1 (v)6 (erage of SUD bene\036ts for )]TJ
-0.044 Tw T*
[(CHIP clients beginning in federal \036scal y)6 (ear 2020 and makes )]TJ
0.22 Tw T*
[(it )0.5 (easier )0.6 (for )0.6 (M)24 (edicar)10 (e )0.5 (patients )0.6 (to )0.6 (access )0.5 (MA)70 (T )0.6 (and )0.5 (SUD )]TJ
0.574 Tw T*
[(telehealth ser)-18 (vices. \037e SUPPOR)45 (T for P)42 (atients and )]TJ
-0.087 Tw T*
[(Communities A)12 (ct also allo)12 (ws states to co)16 (v)6.1 (er cer)-8 (tain r)10 (esidential )]TJ
0 Tw T*
[(SUD tr)10 (eatment for M)24.1 (edicaid patients for a limited time.)]TJ
0.075 Tw 0 -2.02 TD
[(\037e opioid crisis will continue to a\034ect )45.3 (T)120 (exas and the U.S. )]TJ
0.159 Tw 0 -1.3 TD
[(\037e state and the federal go)16 (v)6 (ernment hav)6 (e taken steps to )]TJ
-0.042 Tw T*
[(pr)10 (ev)6 (ent )0.6 (ne)-6 (w )0.5 (cases )0.5 (of )0.5 (opioid )0.6 (misuse, )0.6 (abuse, )0.5 (and )0.5 (addiction )0.6 (and )]TJ
0.047 Tw T*
[(to )0.5 (tr)10 (eat )0.5 (existing )0.5 (patients )0.5 (with )0.5 (OUD. )0.5 (I)24 (t is )0.5 (impor)-7.9 (tant )0.5 (for )0.5 (the )]TJ
0.215 Tw T*
[(state to monitor its pr)6 (ogr)10 (ess in addr)10 (essing the epidemic, )]TJ
0.292 Tw T*
[(par)-8 (ticularly in impr)6.1 (o)16 (ving access to tr)10 (eatment. I)24 (t also is )]TJ
0.019 Tw T*
[(impor)-7.9 (tant for the state to continue to take adv)6 (antage of any )]TJ
0 Tw T*
[(federal funding oppor)-7.8 (tunities to combat the crisis.)]TJ
ET
endstream
endobj
51 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
1 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 54 720 cm
0 0 m
486 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 54 724.353 Tm
[(O)39.8 (VER)80.1 (VIEW OF OPIOID CRISIS IN )125.3 (TEXAS)]TJ
ET
endstream
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 75.672 45.7366 Tm
[(LEGISLA)99.4 (TIVE BUDGET BO)39.9 (ARD ST)100.2 (AFF REPOR)89.6 (TS \226 ID:)100.2 ( 4830)]TJ
/Span<>> BDC
( )Tj
EMC
36.2 0 Td
[(LEGISLA)99.4 (TIVE BUDGET BO)39.9 (ARD ST)100.2 (AFF \226 )100 (APRIL 2019)]TJ
ET
0 0 0 1 K
1 w 4 M 0 j 0 J
q 1 0 0 1 54 56.524 cm
0 0 m
486 0 l
S
Q
endstream
endobj
53 0 obj
<>
endobj
54 0 obj
<>
endobj
55 0 obj
<>stream
H\j0EY6Cp xu4N
,dg`RܫQRϵgHh
8`.xro$74PnZC79,t7"yCU5H?8!]zik; $kضqm;x|]g|3Z|k0Bqq+t
Bt8M$t\1g9sN\0ĒYG#Y$Mɚ4%HґYw{=1KҗsE|fkŹ(E"/Wtž|*UHY^5*k>